NCT00093223View on ClinicalTrials.gov

A Safety Study of ABI-007 for In-Stent Restenosis

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 1, 2001

Primary Completion Date

December 1, 2007

Study Completion Date

December 1, 2007

Conditions
Angina PectorisCoronary Artery Disease
Interventions
DRUG

Paclitaxel Nanoparticle Albumin Bound

Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).

DRUG

Paclitaxel Nanoparticle Albumin Bound

DRUG

Paclitaxel Nanoparticle Albumin Bound

35mg/35 infusion time is 3.5 minutes

Trial Locations (1)

27703

Abraxis BioScience, Inc., Durham

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY